Valeant Pharmaceuticals (VRX) Posts Q1 EPS of 99c; Boosts FY12 Outlook

Article Stock Quotes (1) Comments (0)

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $0.99, versus $0.02 reported in the same period last year.

Valeant Pharmaceuticals International, Inc. sees FY2012 EPS of $4.45-$4.70, versus prior guidance of $3.95-$4.20. Valeant Pharmaceuticals International, Inc. sees FY2012 revenue of $3.4-$3.6 billion.

For earnings history and earnings-related data on Valeant Pharmaceuticals International, Inc. (VRX) click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Hewlett-Packard Company (HPQ) Tops Q2 EPS by 6c as Sales Slide 10%
• Gordmans Stores, Inc. (GMAN) Tops Q1 EPS Views; Issues Light Q2 Outlook
• Perry Ellis Int'l (PERY) Misses Q1 EPS by 1c; Reaffirms Outlook

Create E-mail Alert Related Categories

Earnings, Guidance, Hot Guidance

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?